Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

Amgen

Biotechnology / Immunology

AMGN · Nasdaq · USA

Share price · AMGN

$403.04+28.89 (+7.72%) 3M

close as of 2026-10-02 · 24h delayed · vol 3.5M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Research

See what was announced around each unusual move

Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.

Assets

(31 total)
31Total Assets
19Approved
8Phase 3 / Filed
4Phase 1–2 / Early
16Diseases
Quick filter:
Showing 31 of 31 assets
Target & Modality
Approved
TNF-alpha
Inflammatory Bowel DiseasePsoriatic Arthritis
Ulcerative Colitis, Crohn's Disease
Approved
VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic
Age-Related Macular Degeneration
Approved
Interleukin-1 receptor (IL-1R) · Interleukin-1 receptor type 1 (IL-1R1)Protein / enzyme therapeutic
Rheumatoid Arthritis
apremilast(Otezla)
Approved
PDE4Small molecule
Psoriatic ArthritisPsoriasis
Avacopan(Tavneos)
Approved
Complement C5a receptor 1 (C5aR1/CD88)Small molecule
Chronic Kidney DiseaseSystemic Lupus Erythematosus
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung Cancer
Approved
ProteasomeSmall molecule
Multiple Myeloma
Approved
RANKLMonoclonal antibody
Non-Small Cell Lung CancerMultiple MyelomaRheumatoid ArthritisBreast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
—Monoclonal antibody
Migraine
etanercept(Enbrel)
Approved
TNF-alpha · TNF-alpha / TNF-beta (lymphotoxin-alpha)Protein / enzyme therapeutic
Psoriatic ArthritisPsoriasisRheumatoid Arthritis
Etelcalcetide(Parsabiv)
Approved
Calcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPeptide
Chronic Kidney Disease
Evolocumab(Repatha)
Approved
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular Disease
HZT-501(Duexis)
Approved
Cyclooxygenase (COX-1/COX-2) plus histamine H2 receptorSmall molecule
Rheumatoid Arthritis
Approved
TNF-alpha
Inflammatory Bowel DiseasePsoriatic Arthritis
Ulcerative Colitis, Crohn's Disease
Ivabradine(Corlanor)
Approved
If (funny) channelSmall molecule
Heart Failure

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Unlock with Research ↗
Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Unlock with Research ↗
Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.